Nexalin Technology Inc. has announced plans to initiate new Alzheimer's-focused clinical studies in the third quarter of 2025. The studies will incorporate cognitive testing, imaging biomarkers, and MEG-guided metrics to assess the efficacy of their Deep Intracranial Frequency Stimulation (DIFS™) technology in treating Alzheimer's disease. This initiative follows the reconstitution of Nexalin's Scientific Advisory Board with the appointment of renowned experts Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, who will guide the company's scientific direction and clinical strategy. The move underscores Nexalin's commitment to advancing non-invasive neuromodulation therapies and addressing critical public health challenges related to neurodegenerative diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.